Press Releases
-
Oct 6, 2017- Delisted from NASDAQ effective October 6, 2017 -
Biostage, Inc. ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and...
-
Oct 2, 2017- Presentation with live video webcast Thursday, October 5th at 4:45PM PDT -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening...
-
Aug 14, 2017Closes $3M private placement
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...
-
Aug 7, 2017- Procedure approved via the FDA's single-use expanded access program and was performed at a major U.S. hospital -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...
-
Aug 4, 2017- Conference Call with Live Audio Webcast on Monday, August 14th at 9:00 AM ET -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
